Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma.
Phillips
Paul M
PM
paulphillipsmd@gmail.com
Newman
Steven A
SA
D000284:Administration, Oral; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D004164:Diphosphonates / Q000009:adverse effects*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D007262:Infusions, Intravenous; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016727:Orbital Pseudotumor / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids; D007093:Imidazoles; D000077211:Zoledronic Acid; D011241:Prednisone